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Peroxisome proliferator-activated receptor (PPAR γ) acts as a key regulator on adipo-
cyte differentiation and glucose homeostasis.  
 
PPAR γ has been down regulated in type 2 diabetes.  
 
In silico screening was carried out to find potent agonists for human PPARγ. 
 
Structural analog search  and interaction studies were performed to design an “ideal 
drug” by using the existing  activators which have some adverse effects like fluid         
retention and worsen congestive heart  failure. 
Ligand binding sites 
Ile 281, Phe 282, Gly 284, Cys 285, Ser 289, 
His 323, Ile 326, Tyr 327, Leu 330, Ile 341, 
Met 348, Met 364, His 449, Leu 453, Leu 
469, Tyr 473, HOH 18, HOH 36, HOH 58 
and HOH 92 
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 Binding orientations, binding affinity and binding interactions of the existing activators were compared with the obtained thirteen leads. 
 
Seven leads were proposed having good docking score, interactions and pharmacological properties than existing activators. 
 
Hence, these seven leads can be suggested as novel therapeutics in the treatment of type2 diabetes if tested in animal models. 
  Figure 5: The docking complex of lead 1 and human PPAR γ. 
Figure 3: Graphical representation of filtered compounds.  
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Figure 6: The residues involved in van der Waal and H-bond interactions  
with lead 1– PPARγ docking complex. 
Lead 1 
PPARγ 
 Figure 1:The existing activators of PPAR γ. 
Figure 2: The co-crystal structure of human PPAR γ [1ZGY] with BRL49653. 
Figure 4: Comparative docking scores of leads and  
existing inhibitor. 
Ile 281, Gly 284, Cys 
285, Ser 289, Tyr 327, Ile 
341, Met 348, Met 364 
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